Pfizer Eraxis pricing
Executive Summary
Pfizer launches the antifungal Eraxis (fluconazole) the week of May 15. The wholesale acquisition cost is $90 per 50 mg vial plus diluent, although the hospital price will vary depending on location. FDA approved Eraxis Feb. 17 to treat a variety of types of Candida infections (1"The Pink Sheet" Feb. 22, 2006, p. 3). The average wholesale price for the firm's other Candida infection treatment Vfend (voriconazole) is approximately $110 for 200 mg...
You may also be interested in...
Eraxis Approval May Position Pfizer To Reclaim Diflucan Market Share
FDA approval of Pfizer's echinocandin antifungal Eraxis may represent an opportunity for the company to begin to replace the loss of branded Diflucan
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.